Primary Hyperoxaluria Type 1 (PH1)
0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programsNedosiranN/A1 trial
DCR-PHXCPHASE_21 trial
DCR-PHXCPHASE_31 trial
Active Trials
NCT05993416No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Novo NordiskDCR-PHXC
Novo NordiskDCR-PHXC
Clinical Trials (3)
Total enrollment: 110 patients across 3 trials
Long Term Extension Study in Patients With Primary Hyperoxaluria
Start: Jul 2019Est. completion: Apr 203075 patients
Phase 3Active Not Recruiting
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Start: Oct 2019Est. completion: Jun 202135 patients
Phase 2Completed
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
N/ANo Longer Available
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.